Shapiro 1998 b.
Methods | DESIGN: randomised, double‐blind, placebo‐controlled, parallel‐group, multi‐centre study | |
Participants | SYMPTOMATIC PARTICIPANTS RANDOMLY ASSIGNED: N = 201 ANALYSED: N = 75 INTERVENTION: ICS (budesonide 100 μg/d): 102 CONTROL: ICS (budesonide 400 μg/d): 99 WITHDRAWALS: reported AGE: mean (range) years INTERVENTION: ICS (budesonide 100 μg/d): 11.8 (6‐18) CONTROL: ICS (budesonide 400 μg/d): 11.8 (6‐18) GENDER: male N (%) INTERVENTION: ICS (budesonide 100 μg/d): 76 (74.5) CONTROL: ICS (budesonide 400 μg/d): 85 (85.8) ASTHMA SEVERITY: moderate to severe persistent asthma ASTHMA DURATION: duration of ICS‐dependent asthma: mean (range) years INTERVENTION: ICS (budesonide 100 μg/d): 2.8 (0.5‐11) CONTROL: ICS (budesonide 400 μg/d): 2.4 (0.5‐13) MEAN (± SD) β2‐AGONIST USE (puffs/d): INTERVENTION: ICS (budesonide 100 μg/d): 2.8 CONTROL: ICS (budesonide 400 μg/d): 3.2 DOSE OF ICS AT STUDY ENTRY AND AT RUN‐IN: Participants discontinued their previous ICS at randomisation ATOPY (% of participants): not reported ELIGIBILITY CRITERIA
EXCLUSION CRITERIA
|
|
Interventions | PROTOCOL DURATION
DEVICE: dry powder inhaler DOSE OF ICS
CRITERIA FOR WITHDRAWAL FROM STUDY: reported |
|
Outcomes | As above | |
Notes | As above | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Insufficient information on sequence generation |
Allocation concealment (selection bias) | Unclear risk | Insufficient information |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | Blinding of participants and key study personnel ensured |
Blinding of outcome assessment (detection bias) All outcomes | Low risk | Blinding of participants and key study personnel ensured |
Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing outcome data |
Selective reporting (reporting bias) | Low risk | Study protocol not available but published reports include all expected outcomes, including those that were prespecified |
Other bias | Low risk | Study apparently free of other sources of bias |